(Total Views: 852)
Posted On: 06/09/2020 8:36:18 AM
Post# of 153887
Zuess,
Yes. This is the conference call we were expecting.
Obviously there will be "color" on the request for more float. This is important because we will know what is the strategy going forward. I strongly suspect a combination of things:
Up-Listing
Freedom to pursue 10 P2 in Oncology
Potential deal(s) with Bank(s)
In regards to the communication a RED FLASING sign is the NASH reference and/or Dr. Scott Kelly presence in the conference.
NASH is the lowest hanging fruit if we can demonstrate is a fruit. Trials in this indication are long, costly and difficult. However the prize is humongous.
There is no scarcity of BPs chasing a good drug that can help, more so after recent failures in this area (GenFit, Gilead (some), Boehringer, Conatus-Novartis).
Let's hope that the animal study is giving fruit (pun intended) and we will have some results with will enable a good potential, either partnership or juicy licensing deal down the road.
Yes. This is the conference call we were expecting.
Obviously there will be "color" on the request for more float. This is important because we will know what is the strategy going forward. I strongly suspect a combination of things:
Up-Listing
Freedom to pursue 10 P2 in Oncology
Potential deal(s) with Bank(s)
In regards to the communication a RED FLASING sign is the NASH reference and/or Dr. Scott Kelly presence in the conference.
NASH is the lowest hanging fruit if we can demonstrate is a fruit. Trials in this indication are long, costly and difficult. However the prize is humongous.
There is no scarcity of BPs chasing a good drug that can help, more so after recent failures in this area (GenFit, Gilead (some), Boehringer, Conatus-Novartis).
Let's hope that the animal study is giving fruit (pun intended) and we will have some results with will enable a good potential, either partnership or juicy licensing deal down the road.
(4)
(0)
